Medical Considerations: Semaglutide or Tirzepatide, including micro-dose programs, cannot be prescribed and should not be purchased by individuals with a BMI under 25 (or under 20 for micro-dosing), an eating disorder, diabetes, gallbladder disease, history of drug or alcohol abuse, recent bariatric surgery, pancreatitis, medullary thyroid cancer or a family history of it, diabetic retinopathy, multiple endocrine neoplasia type 2, or those who are pregnant, breastfeeding, or planning to become pregnant
Kang S, Amagai M, Bruckner AL, et al
May your vendors stay reliable, your peptides stay pure, and your research outcomes stay successful
The blend is used in research on the hypothalamic-pituitary growth hormone axis
BioDrugs , 38 (1), 5-22